|
U.S. Food and Drug Administration approves Opdivo® (nivolumab) + Yervoy® (ipilimumab) for patients with hepatocellular carcinoma (HCC) previously treated with sorafenib
|
11 March 2020 |
|
Voluntis and Bristol-Myers Squibb to co-develop digital therapeutics for oncology
|
04 March 2020 |
|
BioMotiv and Bristol-Myers Squibb announce the launch of Anteros Pharmaceuticals
|
04 February 2020 |
|
U.S. Food and Drug Administration accepts for Priority Review Bristol-Myers Squibb's application for Opdivo (nivolumab) plus Yervoy (ipilimumab) in first-line non-small cell lung cancer
|
17 January 2020 |
|
Bristol-Myers Squibb completes divestment of manufacturing facility in Anagni, Italy
|
07 January 2020 |
|
Bristol-Myers Squibb completes acquisition of Celgene, creating a leading biopharma company
|
21 November 2019 |
|
Bristol-Myers Squibb and Pfizer announce randomized, controlled trial to evaluate the effect of atrial fibrillation screening on health outcomes in older individuals
|
15 November 2019 |
|
Bristol-Myers Squibb awards "Golden Tickets" for LabCentral to Carmine Therapeutics, STIMIT
|
31 October 2019 |
|
The Bristol-Myers Squibb-Pfizer Alliance and Fitbit collaborate to address gaps in atrial fibrillation detection with the aim of accelerating diagnosis
|
18 October 2019 |
|
Bayer, Bristol-Myers Squibb and Ono Pharmaceutical enter into a clinical collaboration agreement
|
18 July 2019 |
|
Bristol-Myers Squibb provides update on pending merger with Celgene
|
24 June 2019 |
|
Bristol-Myers Squibb announces post-closing leadership team
|
05 June 2019 |
|
Award-winning actor and producer Sterling K. Brown joins Bristol-Myers Squibb in effort to share stories of What It's Like to Live with Cancer Today
|
16 May 2019 |
|
Bristol-Myers Squibb reports first quarter financial results
|
25 April 2019 |
|
Bristol-Myers Squibb shareholders approve Celgene acquisition
|
12 April 2019 |
|
European Commission approves Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) for first-line treatment of patients with intermediate- and poor-risk advanced renal cell carcinoma
|
15 January 2019 |
|
Bristol-Myers Squibb to acquire Celgene to create a premier innovative biopharma company
|
03 January 2019 |
|
Bristol-Myers Squibb and Boston Medical Center announce research collaboration to investigate markers of immuno-oncology response and resistance
|
17 December 2018 |
|
Bristol-Myers Squibb awards "Golden Tickets" for LabCentral to ReviveMed, Strand Therapeutics
|
26 November 2018 |
|
Bristol-Myers Squibb and Compugen announce clinical collaboration to evaluate therapeutic regimen in advanced solid tumors
|
11 October 2018 |